Explore 3 Stock Ideas & Industry Insights Download Free Report

News

LENSAR, Inc (NASDAQ:LNSR) Shares Slip: What's Pressuring It and What Comes Next?

● In fact, the recent news flow has been positive: alongside the strong quarter, Lake Street raised its price target on LENSAR to $13 from $10 on 20 August while maintaining a bullish stance.

Vinay Lochav | 10 September 2026

Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the Spotlight: A Pending Kuva Labs Buyout Defines the Outlook

● The modest positive session in the original framing is a price move, not a discrete catalyst; the meaningful driver is the pendingAcquisitionitself.

Vinay Lochav | 10 September 2026

Lantern Pharma (NASDAQ:LTRN) Stock: A Busy News Cycle Meets a Lagging Share Price

Lantern Pharma has spent 2026 leaning hard into a pitch that blends oncologyDrug Developmentwith artificial intelligence, and the small-cap has generated a steady stream of announcements. Yet the stock has drifted lower, trading near $1.77 in early September with a marketCapitalizationaround $23 million. For …

Vinay Lochav | 10 September 2026

Lineage Cell Therapeutics (NYSE American:LCTX) Slips 5.5% Despite Its Genentech Backing

A roughly 5.5% single-session drop in Lineage Cell Therapeutics, Inc (NYSE American:LCTX) fits a pattern familiar to small-cap biotech investors: sharp moves with no obvious explanation. Underneath that daily swing sits a more durable story, a clinical-stage developer of allogeneic cell therapies anchored by …

Vinay Lochav | 10 September 2026

LENZ Therapeutics (NASDAQ:LENZ) Stock: Is This a Point Worth Examining

LENZ Therapeutics, Inc (NASDAQ:LENZ) has spent 2026 transitioning from a clinical-stage hopeful into a commercial eye-care company, and its shares have been volatile as investors gauge the early trajectory of its first approved product.

Vinay Lochav | 10 September 2026

LifeVantage (NASDAQ: LFVN) Shares Tick Up: The Next Catalyst to Watch

After a difficult fiscal year, LifeVantage Corporation (NASDAQ: LFVN) is drawing renewed interest from small-cap investors trying to gauge whether a turnaround is taking shape. The nutrition and personal-care company's shares recently ticked higher to around $6.51, giving it a marketCapitalizationnear $82 million, and …

Vinay Lochav | 10 September 2026

LianBio (OTC:LIANY) Turns Lower: Why Investors Are Reassessing the Stock

● LianBio was built to in-license and develop therapies for the Greater China and broader Asian markets, assembling a portfolio that included the cardiovascular drug mavacamten and other candidates licensed from Western partners.

Vinay Lochav | 10 September 2026

Lunai Bioworks (NASDAQ:LNAI) Stock: Why It Could Still Be One to Watch

A near-flatTrading sessioncan hide a surprisingly eventful corporate story. Lunai Bioworks Inc. (NASDAQ:LNAI) barely moved in its most recent session, yet the company behind the ticker has been anything but static: a fresh name, a reverse stock split, a blood-brain-barrierAcquisitionand new research collaborations have …

Vinay Lochav | 10 September 2026

ChromoCure's (OTC:KKUR) Cancer-Detection Concept Has No SEC Filings Behind It

ChromoCure, Inc (OTC:KKUR) sits at the far, speculative edge of the health-technology market: a nano-cap over-the-counter security quoted at a small fraction of a penny. There is no confirmed recent catalyst, no verifiable stream of company news, and very little public financial disclosure to …

Nitish Kishor | 10 September 2026

Keros Therapeutics (NASDAQ: KROS) Turns Positive: Why It Belongs on the September 2026 Watchlist

After a turbulent stretch, Keros Therapeutics (NASDAQ: KROS) has become a study in strategic focus. The clinical-stage biopharmaceutical company spent much of 2025 reshaping its pipeline and leadership, and it enters the autumn of 2026 as a leaner developer concentrated on a single lead …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…